RT Journal Article
SR Electronic
T1 Changing of therapeutic trends between the 1st and 2nd wave did not reduce COVID-19 related mortality of renal transplant recipients: a national registry study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.15.21267794
DO 10.1101/2021.12.15.21267794
A1 Bastien Berger
A1 Marc Hazzan
A1 Nassim Kamar
A1 Hélène Francois
A1 Marie Matignon
A1 Clarisse Greze
A1 Philippe Gatault
A1 Luc Frimat
A1 Pierre F Westeel
A1 Valentin Goutaudier
A1 Renaud Snanoudj
A1 Charlotte Colosio
A1 Antoine Sicard
A1 Dominique Bertrand
A1 Christiane Mousson
A1 Jamal Bamoulid
A1 Antoine Thierry
A1 Dany Anglicheau
A1 Lionel Couzi
A1 Jonathan M Chemouny
A1 Agnes Duveau
A1 Valerie Moal
A1 Yannick Le Meur
A1 Gilles Blancho
A1 Jérôme Tourret
A1 Paolo Malvezzi
A1 Christophe Mariat
A1 Jean-Philippe Rerolle
A1 Nicolas Bouvier
A1 the French SOT COVID Registry
A1 Sophie Caillard
A1 Olivier Thaunat
YR 2021
UL http://medrxiv.org/content/early/2021/12/16/2021.12.15.21267794.abstract
AB SARS-CoV-2 pandemic evolved in two consecutive waves over 2020 (for France: 1st wave from March 1 to July 31; and 2nd wave from August 1 to December 31). Improvements in the management of COVID-19 led to a reduction of mortality rates in hospitalized patients during the second wave. Whether this progress also benefited to kidney transplant recipients (KTR), a population particularly vulnerable to severe COVID-19, remained unclear.In France, 957 KTR were hospitalized for COVID-19 in 2020 and their data were prospectively collected in the French SOT COVID registry. The presentation, management, and outcomes of the 359 KTR diagnosed during the 1st wave were compared to those of the 598 of the 2nd wave. Baseline comorbidities were largely similar between KTR of the 2 waves. Maintenance immunosuppression was reduced in most patients but withdrawal of antimetabolite (73.7% vs 58.4%, p<0.001) or CNI (32.1% vs 16.6%, p<0.001) was less frequent during the 2nd wave. Hydroxychloroquine and azithromycin that were commonly used during the 1st wave (21.7% and 30.9%, respectively) were almost abandoned during the 2nd. In contrast, the use of high dose corticosteroids doubled (19.5% vs. 41.6%, p<0.001). Despite these changing trends in COVID-19 management, 60-day mortality was not statistically different between the 2 waves (25.3% vs. 23.9%; Log Rank, p=0.48).We conclude that changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality in KTR. Our data indirectly support the importance of vaccination and monoclonal neutralizing anti-SARS-CoV-2 antibodies to protect KTR from severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOT is supported by the Etablissement Francais du Sang and the Fondation pour la Recherche Medicale (PME20180639518).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective registry was approved by the Institutional Review Board of Strasbourg University (approval number 02.26) and registered at clinicaltrials.gov (NCT04360707).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors